Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group

Michael Leisch; M Pfeilstocker; R Stauder; S Heibl; H Sill; M Girschikofsky; M Stampfl-Mattersberger; C Tinchon; B Hartmann; A Petzer; M Schreder; D Kiesl; S Vallet; Alexander Egle; Thomas Melchardt; G Piringer; A Zebisch; S Machherndl-Spandl; D Wolf; F Keil; M Drost; Richard Greil; Lisa Pleyer

doi:10.3390/cancers14102459

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group

Michael Leisch^* (First author), M Pfeilstocker, R Stauder, S Heibl, H Sill, M Girschikofsky, M Stampfl-Mattersberger, C Tinchon, B Hartmann, A Petzer, M Schreder, D Kiesl, S Vallet, Alexander Egle (Co-author), Thomas Melchardt (Co-author), G Piringer, A Zebisch, S Machherndl-Spandl, D Wolf, F KeilM Drost, Richard Greil (Co-author), Lisa Pleyer (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article (Journal) › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	2459
Journal	Cancers
Volume	14
Issue number	10
DOIs	https://doi.org/10.3390/cancers14102459
Publication status	Published - 2022

Keywords

ACUTE MYELOID-LEUKEMIA
RISK MYELODYSPLASTIC SYNDROMES
CONVENTIONAL CARE REGIMENS
REAL-WORLD
CLINICAL-PRACTICE
MDS PATIENTS
AML
MANAGEMENT
DIAGNOSIS
EFFICACY

Access to Document

10.3390/cancers14102459

Cite this

Leisch, M., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Hartmann, B., Petzer, A., Schreder, M., Kiesl, D., Vallet, S., Egle, A., Melchardt, T., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., ... Pleyer, L. (2022). Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. Cancers, 14(10), 2459. https://doi.org/10.3390/cancers14102459

@article{682e3b9b0d1c4ccda80b719bca1d7942,

title = "Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group",

keywords = "ACUTE MYELOID-LEUKEMIA, RISK MYELODYSPLASTIC SYNDROMES, CONVENTIONAL CARE REGIMENS, REAL-WORLD, CLINICAL-PRACTICE, MDS PATIENTS, AML, MANAGEMENT, DIAGNOSIS, EFFICACY",

author = "Michael Leisch and M Pfeilstocker and R Stauder and S Heibl and H Sill and M Girschikofsky and M Stampfl-Mattersberger and C Tinchon and B Hartmann and A Petzer and M Schreder and D Kiesl and S Vallet and Alexander Egle and Thomas Melchardt and G Piringer and A Zebisch and S Machherndl-Spandl and D Wolf and F Keil and M Drost and Richard Greil and Lisa Pleyer",

note = "[Egle, A; Greil, R; Leisch, M; Melchardt, T; Pleyer, L] 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria ",

year = "2022",

doi = "10.3390/cancers14102459",

language = "English",

volume = "14",

pages = "2459",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "10",

}

Leisch, M, Pfeilstocker, M, Stauder, R, Heibl, S, Sill, H, Girschikofsky, M, Stampfl-Mattersberger, M, Tinchon, C, Hartmann, B, Petzer, A, Schreder, M, Kiesl, D, Vallet, S, Egle, A , Melchardt, T, Piringer, G, Zebisch, A, Machherndl-Spandl, S, Wolf, D, Keil, F, Drost, M, Greil, R & Pleyer, L 2022, 'Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group', Cancers, vol. 14, no. 10, pp. 2459. https://doi.org/10.3390/cancers14102459

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. / Leisch, Michael (First author); Pfeilstocker, M; Stauder, R et al.
In: Cancers, Vol. 14, No. 10, 2022, p. 2459.

Research output: Contribution to journal › Original Article (Journal) › peer-review

TY - JOUR

T1 - Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group

AU - Leisch, Michael

AU - Pfeilstocker, M

AU - Stauder, R

AU - Heibl, S

AU - Sill, H

AU - Girschikofsky, M

AU - Stampfl-Mattersberger, M

AU - Tinchon, C

AU - Hartmann, B

AU - Petzer, A

AU - Schreder, M

AU - Kiesl, D

AU - Vallet, S

AU - Egle, Alexander

AU - Melchardt, Thomas

AU - Piringer, G

AU - Zebisch, A

AU - Machherndl-Spandl, S

AU - Wolf, D

AU - Keil, F

AU - Drost, M

AU - Greil, Richard

AU - Pleyer, Lisa

N1 - [Egle, A; Greil, R; Leisch, M; Melchardt, T; Pleyer, L] 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria

PY - 2022

Y1 - 2022

KW - ACUTE MYELOID-LEUKEMIA

KW - RISK MYELODYSPLASTIC SYNDROMES

KW - CONVENTIONAL CARE REGIMENS

KW - REAL-WORLD

KW - CLINICAL-PRACTICE

KW - MDS PATIENTS

KW - AML

KW - MANAGEMENT

KW - DIAGNOSIS

KW - EFFICACY

U2 - 10.3390/cancers14102459

DO - 10.3390/cancers14102459

M3 - Original Article (Journal)

C2 - 35626063

SN - 2072-6694

VL - 14

SP - 2459

JO - Cancers

JF - Cancers

IS - 10

ER -